UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Journal of the neurological sciences, 2020-05, Vol.412, p.116803-116803, Article 116803

2020

Volltextzugriff (PDF)

Complement Inhibitor Therapy for Myasthenia Gravis

Frontiers in immunology, 2020-06, Vol.11, p.917

2020

Volltextzugriff (PDF)

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Lancet neurology, 2023-07, Vol.22 (7), p.578-590

2023

Volltextzugriff (PDF)

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis

Expert opinion on investigational drugs, 2021-05, Vol.30 (5), p.483-493

2021

Volltextzugriff (PDF)

Improvement of fatigue in generalised myasthenia gravis with zilucoplan

Journal of neurology, 2024-05, Vol.271 (5), p.2758-2767

2024

Volltextzugriff (PDF)

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Journal of neurology, 2023-08, Vol.270 (8), p.3862-3875

2023

Volltextzugriff (PDF)

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

Lancet neurology, 2020-12, Vol.19 (12), p.970-971

2020

Volltextzugriff (PDF)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and therapy, 2023-10, Vol.12 (5), p.1435-1438

2023

Volltextzugriff (PDF)

The Relationship between Trans-Lesional Conduction, Motor Neuron Pool Excitability, and Motor Function in Dogs with Incomplete Recovery from Severe Spinal Cord Injury

Journal of neurotrauma, 2017-11, Vol.34 (21), p.2994-3002

2017

Volltextzugriff (PDF)

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence

Neuropsychiatric disease and treatment, 2023-01, Vol.19, p.2639-2655

2023

Volltextzugriff (PDF)

Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitment

The Journal of clinical investigation, 2018-10, Vol.128 (10), p.4727-4741

2018

Volltextzugriff (PDF)

Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review

Neurology, 2017-09, Vol.89 (10), p.1069-1077

2017

Volltextzugriff (PDF)

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Frontiers in neurology, 2024-01, Vol.14, p.1284444-1284444

2024

Volltextzugriff (PDF)

Score fluctuation might be associated with a higher placebo rate in the RAISE trial – Authors' reply

Lancet neurology, 2023-11, Vol.22 (11), p.982-983

2023

Volltextzugriff (PDF)

Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis

Autoimmunity (Chur, Switzerland), 2016-11, Vol.49 (7), p.472-479

2016

Volltextzugriff (PDF)

Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy

Neuroepidemiology, 2023-05, Vol.57 (2), p.90-99

2023

Volltextzugriff (PDF)

Electrodiagnosis of Disorders of Neuromuscular Transmission

Physical medicine and rehabilitation clinics of North America, 2013-02, Vol.24 (1), p.169-192

Howard, James F., MD

2013

Volltextzugriff (PDF)

Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient Dogs

Molecular therapy, 2010-08, Vol.18 (8), p.1501-1508

2010

Volltextzugriff (PDF)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

Journal of neurology, 2023-06, Vol.270 (6), p.3129-3137

2023

Volltextzugriff (PDF)

Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies

Mammalian genome, 2012-02, Vol.23 (1-2), p.85-108

2012

Volltextzugriff (PDF)

De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis of current clinical trials

European journal of cancer (1990), 2014-10, Vol.50 (15), p.2636-2648

2014

Volltextzugriff (PDF)

Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States

Orphanet journal of rare diseases, 2023-03, Vol.18 (1), p.65-65, Article 65

2023

Volltextzugriff (PDF)

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study

Frontiers in neurology, 2020-11, Vol.11, p.556104-556104

2020

Volltextzugriff (PDF)

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

Neurology, 2023-09, Vol.101 (10), p.442-451

2023

Volltextzugriff (PDF)

Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity

Proceedings of the National Academy of Sciences - PNAS, 2022-01, Vol.119 (4), p.1

2022

Volltextzugriff (PDF)

1 – 25 von 2.545

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.031)
Mit Volltextzugriff
(1.728)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.445)
Life Sciences & Biomedicine
(1.261)
Humans
(1.082)
Male
(671)
Female
(627)
Biological And Medical Sciences
(450)
Middle Aged
(430)
Medical Sciences
(393)
Adult
(380)
Aged
(327)
Animals
(228)
Neurosciences & Neurology
(185)
General & Internal Medicine
(145)
Clinical Neurology
(140)
Adolescent
(133)
Cardiovascular System & Cardiology
(131)
Retrospective Studies
(131)
Surgery
(131)
Treatment Outcome
(131)
Aged, 80 And Over
(127)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Complement Inhibitor Therapy for Myasthenia Gravis

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis

Improvement of fatigue in generalised myasthenia gravis with zilucoplan

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

The Relationship between Trans-Lesional Conduction, Motor Neuron Pool Excitability, and Motor Function in Dogs with Incomplete Recovery from Severe Spinal Cord Injury

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence

Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitment

Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Score fluctuation might be associated with a higher placebo rate in the RAISE trial – Authors' reply

Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis

Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy

Electrodiagnosis of Disorders of Neuromuscular Transmission

Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient Dogs

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies

De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis of current clinical trials

Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity

Aktive Filter

Suchergebnisse filtern